default author photo

COVE Study Group

United States

SCHOLARLY PAPERS

1

DOWNLOADS

127

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial

Number of pages: 40 Posted: 29 Dec 2021
Baylor College of Medicine, Harvard University - Brigham and Women’s Hospital, Meridian Clinical Research, Duke University - Duke Human Vaccine Institute, Government of the United States of America - Vaccine Research Center, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, Government of the United States of America - VA Greater Los Angeles Healthcare System (GLA), Rutgers, The State University of New Jersey - New Jersey Medical School, Lynn Health Science Institute (Lynn Institute), DM Clinical Research - Texas Center for Drug Development (TCDD), DM Clinical Research, Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc. and Independent
Downloads 127 (572,948)

Abstract:

Loading...

mRNA-1273, immunogenicity, antibodies, SARS-CoV-2, vaccine